JBJennifer Barcroft

Jennifer Barcroft

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jennifer Barcroft has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Tom Bourne

    Department of Development and Regeneration, KU Leuven, Leuven, Belgium

    7 shared publications
  • Christopher Kyriacou

    Tommy's National Centre for Miscarriage Research, Early Pregnancy and Acute Gynaecology Unit, Department of Obstetrics and Gynaecology, Queen Charlotte's and Chelsea Hospital, Imperial College London, London, UK

    5 shared publications
  • Nina Parker

    Tommy's National Centre for Miscarriage Research Imperial College London London United Kingdom

    5 shared publications
  • C. Stalder

    Early Pregnancy and Acute Gynecology Unit Queen Charlotte's and Chelsea Hospital, Imperial College London London United Kingdom

    4 shared publications
  • S. Sur

    Early Pregnancy and Acute Gynecology Unit Queen Charlotte's and Chelsea Hospital, Imperial College London London United Kingdom

    3 shared publications
  • Shabnam Bobdiwala

    Tommy's National Centre for Miscarriage Research Imperial College London London United Kingdom

    3 shared publications

Latest Publications

  • Open Access

    Diagnostic imaging of adnexal lesions in pregnancy: systematic review

    by N. Cooper, N. Kotecha, A. Novak, J. Barcroft, J. Yazbek, C. Landolfo, M. Al‐Memar, D. Timmerman, S. Saso, T. Bourne

    Objective: To describe the imaging features of adnexal lesions during pregnancy and assess the performance of current models for the risk assessment of such lesions. Methods: This was a PROSPERO‐registered systematic review including studies published from inception to 1 August 2025 and was performed as per Preferred Reporting Systems for Systematic Reviews and Meta‐Analysis guidance using Covidence software. Studies were included if they utilized an objective or standardized assessment of imaging features (based on the International Ovarian Tumor Analysis (IOTA) terms and definitions, or predefined categorical variables), expert description or quantitative data (such as lesion measurements and number of papillary projections) to assess the risk of adnexal lesions during pregnancy. Standardized extraction of imaging features was performed and classification of outcomes was based on histology, resolution or expert impression. Diagnostic model performance was also extracted. Meta‐analysis of model performance was not performed owing to study heterogeneity. Results: Overall, 3349 studies were screened, of which 40 underwent full‐text review and 16 were included in the systematic review, comprising 1674 patients and 1660 adnexal lesions. Most included studies were retrospective and ultrasound‐based. Excluding six studies that exclusively reported benign lesions, 93.1% (1284/1379) of patients had benign lesions, 3.4% (47/1379) had borderline ovarian tumors (BOTs) and 3.5% (48/1379) had malignant lesions. Excluding studies reporting exclusively on endometrioma, the most common benign adnexal lesions were simple cysts (39.0% (393/1007)), mature cystic teratomas (24.2% (244/1007)) and endometriomas (14.9% (150/1007)). Malignant lesions were most often epithelial ovarian cancer or metastases. Both BOTs and malignant lesions retained imaging characteristics comparable with those observed in non‐pregnant women. Decidualization was present in 11.8–39.5% of reported endometriomas. While decidualized endometriomas (DEs) and BOTs typically share characteristics, experts noted distinguishing morphological features and behaviors. BOTs were larger (median, 88.0 mm vs 48.1 mm), and although both were predominantly unilocular‐solid lesions, BOTs were relatively more often multilocular‐solid (30.0% vs 22.4%) compared with DEs. Both showed high vascularity, with most cases having a color score of 3. Most DEs (83.9%) had one to three papillary projections, whereas most BOTs (66.7%) had more than three papillary projections. Diagnostic models, such as the IOTA two‐step strategy and the Assessment of Different NEoplasias in the adneXa model alone, showed high specificity (70.0–90.2%) and negative predictive value (90.0–98.3%), but performance was limited by misclassification of DEs as malignant. Conclusions: Ultrasound can reliably assess adnexal lesions in pregnancy. DEs and BOTs can appear similar owing to their morphological overlap. Both BOTs and malignant lesions in pregnancy show morphology comparable with that in non‐pregnant women, and IOTA models maintain a high negative predictive value for excluding malignancy in such cases. Future research should refine diagnostic tools to improve the differentiation of benign from malignant cysts with solid components. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

  • Open Access

    Evaluating use of two‐step International Ovarian Tumor Analysis strategy to classify adnexal masses identified in pregnancy: pilot study

    by J. Barcroft, M. Pandrich, S. Del Forno, N. Cooper, K. Linton‐Reid, C. Landolfo, D. Timmerman, S. Saso, T. Bourne

    Objectives: The primary aim was to validate the International Ovarian Tumor Analysis (IOTA) benign simple descriptors (BDs) followed by the Assessment of Different NEoplasias in the adneXa (ADNEX) model, if BDs cannot be applied, in a two‐step strategy to classify adnexal masses identified during pregnancy. The secondary aim was to describe the natural history of adnexal masses during pregnancy.Methods: This was a retrospective analysis of prospectively collected data from women with an adnexal mass identified on ultrasonography during pregnancy between 2017 and 2022 at Queen Charlotte's and Chelsea Hospital, London, UK. Clinical and ultrasound data were extracted from medical records and ultrasound software. Adnexal masses were classified and managed according to expert subjective assessment (SA). Borderline ovarian tumors (BOTs) were classified as malignant. BDs were applied retrospectively to classify adnexal masses, and if BDs were not applicable, the ADNEX model (using a risk‐ of‐malignancy threshold ≥ 10%) was used, in a two‐step strategy. The reference standard was histology (where available) or expert SA at the postnatal ultrasound scan.Results: A total of 291 women with a median age of 33 (interquartile range (IQR), 29–36) years presented with an adnexal mass during pregnancy, at a median gestational age of 12 (IQR, 8–17) weeks. Of those, 267 (91.8%) were followed up to the postnatal period. Based on the reference standard, 4.1% (11/267) of adnexal masses were classified as malignant (all BOTs) and 95.9% (256/267) as benign. BDs were applicable in 68.9% (184/267) of adnexal masses; of these, only one (0.5%) BOT was misclassified as benign. The ADNEX model was used to classify the 83 residual masses and misclassified 3/10 (30.0%) BOTs as benign and 25/73 (34.2%) benign masses as malignant, of which 13/25 (52.0%) were classified as decidualized endometrioma on expert SA. The two‐step strategy had a specificity of 90.2%, sensitivity of 63.6%, negative predictive value of 98.3% and positive predictive value of 21.9%. A total of 56 (21.0%) women underwent surgical intervention: four (1.5%) as an emergency during pregnancy, four (1.5%) electively during Cesarean section and 48 (18.0%) postnatally. During follow‐up, 64 (24.0%) adnexal masses resolved spontaneously. Cyst‐related complications occurred in four (1.5%) women during pregnancy (ovarian torsion, n = 2; cyst rupture, n = 2) and six (2.2%) women in the postnatal period (all ovarian torsion). Overall, 196/267 (73.4%) women had a persistent adnexal mass at postnatal ultrasound. Presumed decidualization occurred in 31.1% (19/61) of endometriomas and had resolved in 89.5% (17/19) by the first postnatal ultrasound scan.Conclusions: BDs apply to most adnexal masses during pregnancy. However, the small number of malignant tumors in this cohort (4.1%) restricted the evaluation of the ADNEX model, so expert SA should be used to classify adnexal masses during pregnancy when BDs do not apply. A larger multicenter prospective study is required to evaluate the use of the ADNEX model to classify adnexal masses during pregnancy. Our data suggest that most adnexal masses can be managed expectantly during pregnancy, given the high rate of spontaneous resolution and low risk of complications. © 2024 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.


  • Open Access

    Ambulatory human chorionic gonadotrophin (hCG) testing: a verification of two hCG point of care devices

    by Christopher Kyriacou, Wei Yang, Shikha Kapur, Shanuja Maheetharan, Margaret Pikovsky, Nina Parker, Jennifer Barcroft, Shabnam Bobdiwala, Shyamaly Sur, Catriona Stalder, et al.

    Objectives: Quantitative human chorionic gonadotropin (hCG) measurements are used to manage women classified with a pregnancy of unknown location (PUL). Two point of care testing (POCT) devices that quantify hCG are commercially available. We verified the i-STAT 1 (Abbott) and the AQT 90 FLEX (Radiometer) prior to use in PUL triage. Methods: Tests for precision, external quality assurance (EQA), correlation, hook effect and recovery were undertaken alongside a POCT usability assessment during this prospective multi-center verification. Results: Coefficients of variation ranged between 4.0 and 5.1 % for the three i-STAT 1 internal quality control (IQC) solutions and between 6.8 and 7.3 % for the two AQT IQC solutions. Symmetric differences in POCT EQA results when compared with laboratory and EQA stock values ranged between 3.2 and 24.5 % for the i-STAT 1 and between 3.3 and 36.9 % for the AQT. Correlation coefficients (i-STAT 1: 0.96, AQT: 0.99) and goodness of fit curves (i-STAT 1: 0.92, AQT: 0.99) were excellent when using suitable whole blood samples. An hCG hook effect was noted with the i-STAT 1 between 572,194 and 799,089 IU/L, lower than the hook effect noted with the AQT, which was between 799,089 and 1,619,309 IU/L. When hematocrit concentration was considered in sample types validated for use with each device, hCG recovery was 108 % with the i-STAT 1 and 98 % with the AQT. The i-STAT 1 scored lower on usability overall (90/130) than the AQT (121/130, p<0.001, Mann-Whitney). Conclusions: Both hCG POCT devices were verified for use in clinical practice. Practical factors must also be considered when choosing which device to use in each unit.


  • Open Access

    OC04.07: The significance of intracavity fluid (or pseudo‐sac) in women classified with a pregnancy of unknown location

    by M. Pikovsky, C. Kyriacou, S. Bobdiwala, N. Parker, J. Barcroft, S. Murugesu, M. Al‐Memar, S. Sur, C. Stalder, T. Bourne

  • Open Access

    Time‐effectiveness and convenience of transvaginal ultrasound probe disinfection using ultraviolet vs chlorine dioxide multistep wipe system: prospective survey study

    by C. Kyriacou, E. Robinson, J. Barcroft, N. Parker, M. Tuomey, C. Stalder, D. Gould, M. Al‐Memar, T. Bourne

    Objectives: To compare the efficiency, ease of use and user satisfaction of two methods of transvaginal ultrasound probe high‐level disinfection: ultraviolet‐C radiation (UV‐C) and a chlorine dioxide multistep wipe system.Methods: This was a prospective survey study. UV‐C units were introduced into a busy early pregnancy assessment service and compared with a multiwipe system for disinfection. Before seeing each patient, healthcare professionals (HCPs) measured with a stopwatch the time taken to complete a cycle of disinfection using either UV‐C or chlorine dioxide multistep wipes and responded to a quick‐response (QR) code‐linked survey. Additional essential tasks that could be completed before seeing the next patient during probe disinfection were also documented. Using another QR code‐linked survey, data on ease of use, satisfaction with the system used and preferred system were collected. The ease of use and satisfaction with the system were rated on a 0 to 10 Likert scale (0 poor, 10 excellent). A free‐text section for comments was then completed.Results: Disinfection using UV‐C (n = 331) was 60% faster than the chlorine dioxide multiwipe system (n = 332) (101 vs 250 s; P < 0.0001). A greater number of tasks were completed during probe disinfection when using UV‐C, saving a further 74 s per patient (P < 0.0001). The HCPs using UV‐C (n = 71) reported greater ease of use (median Likert score, 10 vs 3; P < 0.0001) and satisfaction (median Likert score, 10 vs 2; P < 0.0001) compared with those using the multiwipe system (n = 43). HCPs reported that the chlorine dioxide system was time‐consuming and environmentally unfriendly, while the UV‐C system was efficient and easy to use. Overall, 98% of the HCPs preferred using the UV‐C system.Conclusions: UV‐C technology is more time‐efficient and allows more essential tasks to be completed during disinfection. For a 4‐h ultrasound list of 15 patients, the use of UV‐C would save 55 min 45 s. HCPs found UV‐C preferable and easier to use. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.


  • Open Access

    VP01.01: Ultrasound characteristics, serum biochemistry and outcomes for ectopic pregnancies presenting during the COVID‐19 pandemic: retrospective analysis

    by N.C. Cooper, C. Kyriacou, E. Robinson, N. Parker, J. Barcroft, S. Kundu, P. Letchworth, S. Sur, D. Gould, C. Stalder, et al.

  • Open Access

    OC06.01: Point‐of‐care testing in pregnancy of unknown location outcome prediction

    by C. Kyriacou, S. Kapur, S. Jeyapala, S. Bobdiwala, H. Fourie, N. Parker, J. Barcroft, S. Sur, C. Stalder, S. Syed, et al.